Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
7 studies found for:    15863374 [PUBMED-IDS]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Enrolling by invitation The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men
Conditions: Anal Dysplasia;   Human Papillomavirus;   Anal Cancer
Interventions: Device: The Hyfrecator ® 2000 Electrosurgical System;   Other: Observation Alone
2 Completed Evaluation of Long Term Immunity Following HPV Vaccination
Conditions: Cervical Cancer;   Anogenital Warts
Intervention: Biological: Cervarix®
3 Active, not recruiting Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy.
Conditions: Transplantation;   Systemic Lupus Erythematosus;   Systemic Immune Disease
Intervention: Biological: HPV prophylactic vaccine Gardasil
4 Completed
Has Results 		The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
Conditions: HIV Positive;   Anal Condylomata;   Anal Warts;   HIV Infections
Interventions: Drug: Saline;   Drug: Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
5 Completed Acceptance of Human Papillomavirus Vaccination in Postpartum Women
Conditions: Human Papilloma Virus;   HPV;   Post Partum
Intervention:
6 Unknown † Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men
Conditions: Anal Cancer;   HIV Infections
Intervention: Biological: Gardasil
7 Completed
Has Results 		Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
Conditions: Papillomavirus Infections;   Genital Diseases, Female
Interventions: Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20;   Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40;   Biological: Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80;   Biological: Placebo (mcg) (Aluminum Adjuvant)225;   Biological: Placebo (mcg) (Aluminum Adjuvant) 450
To Top

† Indicates status has not been verified in more than two years